Applied Uv Inc Stock Price, News & Analysis

Applied UV (NasdaqCM: AUVI) has received a significant order from the Tennessee Department of Correction for its Scientific Air S-400 UV-C pathogen-killing technology. This patented system will be implemented in prisons to combat COVID-19 and other pathogens, marking Applied UV's entry into the correctional facilities market. The S-400 boasts a 99.99%+ kill rate and is already in use across various healthcare facilities, addressing airborne infection control effectively. With 21,000 incarcerated individuals managed by TDOC, this represents a vital step in enhancing public health within correctional environments.

Applied UV (NasdaqCM: AUVI) announced a cash dividend of $0.21875 per share for its 10.5% Series A Cumulative Perpetual Preferred Stock, set to be paid on February 15, 2022, to shareholders recorded by February 4, 2022. The company specializes in pathogen elimination technology, leveraging UVC light and catalytic bioconversion for air purification. The announcement underscores Applied UV's commitment to providing shareholder returns while reinforcing its focus on infection control across diverse markets including healthcare and hospitality.

Applied UV (NASDAQ: AUVI) announced the granting of a patent in Hong Kong for its core SteriLumen pathogen-destroying device, expanding its intellectual property portfolio. This development is part of the company's strategy to combat the spread of pathogens through advanced air and surface sterilization technologies. Currently, Applied UV holds 62 patents in various jurisdictions for its disinfection products, which target markets like healthcare, hospitality, and food processing.

Applied UV (NASDAQ:AUVI, AUVIP) announced that underwriters exercised an over-allotment option to purchase an additional 400,000 shares of common stock, generating approximately $1.2 million in gross proceeds. This was part of a previously completed public offering of 2,666,667 shares priced at $3.00 per share. The offering's registration statement was declared effective on December 28, 2021, with a final prospectus filed shortly after. The funds raised will support Applied UV's focus on infection control technology in various markets.

Applied UV (NASDAQ: AUVI, AUVIP) has closed its underwritten public offering of 2,666,667 shares at $3.00 per share, generating approximately $8.0 million in gross proceeds. The company has also granted the underwriters a 45-day option to purchase up to an additional 400,000 shares to cover over-allotments. The proceeds will be used for general corporate purposes, including investments and acquisitions. The offering's registration was effective on December 28, 2021, and the final prospectus was filed on December 30, 2021.

Applied UV (NASDAQ:AUVI, AUVIP) has announced an underwritten public offering of 2,666,667 shares of common stock, priced at $3.00 per share, aiming to raise approximately $8.0 million before expenses. The offering is set to close around December 31, 2021, pending customary conditions. The net proceeds will support general corporate needs, including investments and acquisitions. Additionally, underwriters have a 45-day option to purchase an extra 400,000 shares for over-allotments. EF Hutton is the book-running manager for this offering.

Applied UV (NASDAQ:AUVI) has reviewed its operations and supply chain following recent acquisitions: Akida Holdings, Kes Science and Technology, and Scientific Air Management. The company will relocate its Denver operations to Atlanta, consolidating facilities to reduce costs and enhance synergies. Max Munn has been appointed as Interim CEO after the resignation of James Alecxih. John J. Hayman has been promoted to Interim COO, bringing 18 years of experience in the acquired company. The consolidation aims to streamline marketing and boost revenue through cross-selling diverse product lines.

Applied UV, Inc. (NASDAQ: AUVI) has announced a $0.21875 cash dividend for its 10.5% Series A Cumulative Perpetual Preferred Stock. This dividend will be paid on January 17, 2022, to shareholders on record by January 4, 2022. The company focuses on infection control technologies, utilizing narrow-range ultraviolet light and catalytic bioconversion technology for air purification. With products like Lumicide™ and Airocide®, Applied UV addresses critical health concerns in high-traffic environments.

Applied UV, Inc. (NASDAQ:AUVI) has appointed James Alecxih as its new CEO, effective December 8, 2021, following the resignation of Q Saeed, who will transition to a consulting role. Alecxih brings extensive experience in global sales and distribution of medical devices and healthcare technology. Under Saeed’s leadership, the company achieved a successful IPO and executed several key acquisitions in the disinfection space. The Board expressed confidence that Alecxih's expertise will be vital in driving growth and innovation in pathogen elimination technologies.